Go Pro
NASDAQ:ANGO

AngioDynamics (ANGO) Stock Price, News & Analysis

AngioDynamics logo
$14.79 +0.02 (+0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$14.66 -0.13 (-0.88%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About AngioDynamics Stock (NASDAQ:ANGO)

Advanced

Key Stats

Today's Range
$14.59
$14.93
50-Day Range
$10.91
$14.77
52-Week Range
$8.36
$15.19
Volume
467,485 shs
Average Volume
482,654 shs
Market Capitalization
$611.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50
Consensus Rating
Hold

Company Overview

AngioDynamics, Inc. is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products. Within the peripheral vascular business, the company’s product line features angioplasty balloons, specialty peripheral catheters and ancillary devices used to treat arterial and venous diseases. The interventional oncology division provides percutaneous ablation systems, biopsy needles and oncology-directed fluid management products to support the treatment of kidney, liver and lung tumors through image-guided therapies.

Founded in 1998 under the name UltraSound Device, Inc., the company adopted the AngioDynamics name later that year as it broadened its product focus beyond ultrasound-guided biopsy devices. Over the years, AngioDynamics has expanded through both organic growth and targeted acquisitions, incorporating established technologies to strengthen its oncology and vascular portfolios. Notable transactions include the acquisition of RITA Medical Systems’ oncology assets and the purchase of Visualase, both intended to deepen its interventional oncology offering.

AngioDynamics markets its products in more than 80 countries through direct sales teams and distribution partnerships, with operations spanning North America, Europe, Asia-Pacific and Latin America. The company serves a diverse customer base of hospitals, specialty clinics and physician offices. AngioDynamics is led by President and Chief Executive Officer Jim Clemmer, with co-founder Joseph P. Tomkin serving as Executive Chairman of the Board.

AI Generated. May Contain Errors.

AngioDynamics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

ANGO MarketRank™: 

AngioDynamics scored higher than 67% of companies evaluated by MarketBeat, and ranked 304th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AngioDynamics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    AngioDynamics has a consensus price target of $19.50, representing about 31.8% upside from its current price of $14.79.

  • Amount of Analyst Coverage

    AngioDynamics has only been the subject of 4 research reports in the past 90 days.

  • Read more about AngioDynamics' stock forecast and price target.
  • Earnings Growth

    Earnings for AngioDynamics are expected to grow in the coming year, from ($0.27) to ($0.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AngioDynamics is -17.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AngioDynamics is -17.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AngioDynamics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AngioDynamics' valuation and earnings.
  • Percentage of Shares Shorted

    3.39% of the float of AngioDynamics has been sold short.
  • Short Interest Ratio / Days to Cover

    AngioDynamics has a short interest ratio ("days to cover") of 2.22, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AngioDynamics has recently decreased by 3.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    AngioDynamics does not currently pay a dividend.

  • Dividend Growth

    AngioDynamics does not have a long track record of dividend growth.

  • News Sentiment

    AngioDynamics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for AngioDynamics this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AngioDynamics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    6.00% of the stock of AngioDynamics is held by insiders.

  • Percentage Held by Institutions

    89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AngioDynamics' insider trading history.
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANGO Stock News Headlines

AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Headlines

ANGO Stock Analysis - Frequently Asked Questions

AngioDynamics' stock was trading at $12.84 on January 1st, 2026. Since then, ANGO stock has increased by 15.2% and is now trading at $14.79.

AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings data on Tuesday, July, 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. The medical instruments supplier earned $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative trailing twelve-month return on equity of 5.73% and a negative net margin of 11.48%.
Read the conference call transcript
.

AngioDynamics subsidiaries include these companies: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and others.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
7/14/2026
Today
7/31/2026
Canaccord Genuity's 46th Annual Growth Conference
8/11/2026
Next Earnings (Estimated)
10/01/2026
Fiscal Year End
5/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:ANGO
CIK
1275187
Employees
760
Year Founded
1988

Price Target and Rating

High Price Target
$20.00
Low Price Target
$19.00
Potential Upside/Downside
+31.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.74 million
Net Margins
-11.48%
Pretax Margin
-11.34%
Return on Equity
-5.73%
Return on Assets
-3.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.19
Quick Ratio
1.49

Sales & Book Value

Annual Sales
$320.17 million
Price / Sales
1.91
Cash Flow
$0.32 per share
Price / Cash Flow
46.76
Book Value
$4.13 per share
Price / Book
3.58

Miscellaneous

Outstanding Shares
41,332,000
Free Float
38,852,000
Market Cap
$611.30 million
Optionable
Optionable
Beta
0.34

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ANGO) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners